List of Biostorage/Biorepositories Companies in United Kingdom - 5

Anuva is creating the world's most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery. Anuva is a translational research company that is creating the most diverse Genomic Bio/Data Bank of Asian Populations, which is being utilized for research & development within the pharma industry. Our cohorts and biorepository allow for follow-on clinical and translational studies, which greatly empower drug development opportunities.

Astoriom is a globally recognised leader in outsourced stability storage and biorepository solutions, with over 30 years of industry experience. We specialise in providing comprehensive stability storage and validation services to pharmaceutical companies, biotech firms, medical device manufacturers, and other life science organisations worldwide. Our services ensure the highest standards of quality and compliance, making us a trusted partner in the industry. Why Astoriom: - Expert Team: Our highly experienced and trusted professionals ensure the highest quality of service. With decades of expertise, our team is dedicated to maintaining the integrity of your products. - Extensive Capacity: We offer over half a million cubic feet of storage at all ICH conditions, accommodating a wide range of temperatures from liquid nitrogen-cooled -196C to +60C. This vast capacity allows us to meet diverse client needs efficiently. - State-of-the-Art Systems: Our automated inventory system and 24/7 alarming ensure robust security, and continuous monitoring. Our systems are designed to provide real-time updates and immediate alerts to ensure the safety and stability of your products. - On-Site Engineers: Dedicated service and validation engineers are available on-site, providing immediate support and maintenance ensuring the continuous operation of storage systems. Astoriom's Core Services: - Stability Storage - Biorepository - Accelerated Ageing Testing - Disaster Recovery - Photostability - Thermal Cycling - Validation Service - 24/7/365 On-Call Repair At Astoriom, every sample matters because everyone's health matters. We are committed to treating each sample entrusted to us with the utmost care, providing reliable and innovative solutions worldwide to ensure the integrity and safety of your products.

Cellesce Ltd is a biotechnology company based in Cardiff, Wales, that focuses on organoid research and bioprocessing technologies. Established in 2013, the company specializes in patient-derived organoids (PDOs) for cancer research, utilizing patented bioprocessing technology to standardize and scale organoid production. The company offers several core services, including the development and manufacturing of standardized cancer organoids for large-scale applications such as compound screening and high-throughput drug discovery. Cellesce also provides scale-up solutions to ensure reproducible organoid batches, meeting the needs of pharmaceutical testing. Additionally, it supports drug discovery pipelines with customized organoid models, particularly in oncology. In December 2022, Cellesce was acquired by Molecular Devices, enhancing its capabilities in integrating organoid technology into drug discovery platforms. The company reported $7.8 million in annual revenue for 2024 and operates with a small team, emphasizing its commitment to advancing organoid-based precision medicine.

To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates. We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.